环磷酰胺和阿霉素诱发甲下黑素沉着：病例报告
Cyclophosphamide and Doxorubicin Induced Melanonychia: A Case Report.
作者信息
Prajapati Vivek Bhanubhai, Madhyastha Sharath, Acharya Raviraj, Gopalaswamy Vinaya, Doddamani Akhila
机构信息
Intern, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University , Manipal, Karnataka, India .
Assistant Professor, Department of General Medicine, Kasturba Medical College, Manipal University , Manipal, Karnataka, India .
出版信息
J Clin Diagn Res. 2017 Jan;11(1):OD04-OD05. doi: 10.7860/JCDR/2017/23041.9216. Epub 2017 Jan 1.
Abstract
Chemotherapeutic agents may rarely cause discoloration and hyperpigmentation of the nails. We present a patient who developed blackish discoloration of nails also referred as melanonychia during six cycles of R-CHOP chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) for the treatment of Non Hodgkin Lymphoma (NHL) follicular type. The patient developed blackish brown discoloration in all the nails. As suggested by previous literature evidence the melanonychia could be associated with cyclophosphamide and doxorubicin. According to the Naranjo causality assessment scale, we established that there was a 'probable' association of nail discoloration with the drug.
摘要
化疗药物很少会导致指甲变色和色素沉着过度。我们报告了一名在接受R-CHOP化疗方案（利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松）六个周期治疗滤泡型非霍奇金淋巴瘤（NHL）期间出现指甲变黑（也称为甲下黑素沉着）的患者。该患者所有指甲均出现黑褐色变色。如先前文献证据所示，甲下黑素沉着可能与环磷酰胺和多柔比星有关。根据Naranjo因果关系评估量表，我们确定指甲变色与药物之间存在“可能”的关联。
相似文献
1
Cyclophosphamide and Doxorubicin Induced Melanonychia: A Case Report.环磷酰胺和阿霉素诱发甲下黑素沉着：病例报告
J Clin Diagn Res. 2017 Jan;11(1):OD04-OD05. doi: 10.7860/JCDR/2017/23041.9216. Epub 2017 Jan 1.
2
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.一线使用环磷酰胺、阿霉素、长春新碱和泼尼松（CHOP）或CHOP联合利妥昔单抗（R-CHOP）治疗的非霍奇金淋巴瘤患者的心血管不良事件：一项系统评价和荟萃分析。
Lancet Haematol. 2020 Apr;7(4):e295-e308. doi: 10.1016/S2352-3026(20)30031-4. Epub 2020 Mar 2.
3
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.不适合移植的新诊断套细胞淋巴瘤患者中硼替佐米、利妥昔单抗、环磷酰胺、多柔比星、泼尼松（VR-CAP）与利妥昔单抗、环磷酰胺、多柔比星、长春新碱、泼尼松（R-CHOP）的比较：一项随机、开放标签、3 期研究的最终总生存结果。
Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.
4
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.在预后良好的侵袭性 B 细胞淋巴瘤患者中，与六次利妥昔单抗联合使用相比，四个与六个周期的 CHOP 化疗（FLYER）：一项随机、3 期、非劣效性试验。
Lancet. 2019 Dec 21;394(10216):2271-2281. doi: 10.1016/S0140-6736(19)33008-9.
5
Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.在感染人类免疫缺陷病毒相关非霍奇金淋巴瘤患者中联合使用环磷酰胺、阿霉素、长春新碱和强的松化疗以及高效抗逆转录病毒疗法。
Cancer. 2001 Jan 1;91(1):155-63. doi: 10.1002/1097-0142(20010101)91:1<155::aid-cncr20>3.0.co;2-b.
6
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.在单独使用剂量调整的环磷酰胺、阿霉素、长春新碱和泼尼松龙化疗或联合利妥昔单抗治疗高危非霍奇金淋巴瘤后进行自体外周血干细胞动员。
Chin J Cancer. 2015 Sep 14;34(11):522-30. doi: 10.1186/s40880-015-0045-3.
7
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗新诊断弥漫性大 B 细胞非霍奇金淋巴瘤患者：14 天与 21 天周期强化剂量的 3 期比较。
Lancet. 2013 May 25;381(9880):1817-26. doi: 10.1016/S0140-6736(13)60313-X. Epub 2013 Apr 22.
8
Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.接受聚乙二醇化脂质体阿霉素和利妥昔单抗免疫化疗的非霍奇金淋巴瘤患者间质性肺炎的发病率。
Ann Hematol. 2018 Jan;97(1):141-147. doi: 10.1007/s00277-017-3160-1. Epub 2017 Oct 31.
9
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).与利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松龙相比，利妥昔单抗、环磷酰胺、非聚乙二醇化脂质体阿霉素、长春新碱和泼尼松龙在弥漫性大B细胞淋巴瘤患者一线治疗中的心脏毒性：奥地利癌症药物治疗工作组[Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)的一项随机III期研究。
Eur J Cancer. 2016 May;58:112-21. doi: 10.1016/j.ejca.2016.02.004. Epub 2016 Mar 15.
10
A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.硼替佐米联合利妥昔单抗、环磷酰胺、多柔比星、改良长春新碱和泼尼松治疗未经治疗的滤泡性淋巴瘤和其他低级别 B 细胞淋巴瘤的 1 期剂量递增研究。
Cancer. 2012 Jul 15;118(14):3538-48. doi: 10.1002/cncr.26660. Epub 2012 Jan 3.
引用本文的文献
1
Drug-Induced Pigmentation: A Review.药物诱导性色素沉着：综述。
Drugs. 2024 Sep;84(9):1071-1091. doi: 10.1007/s40265-024-02062-z. Epub 2024 Aug 1.
2
Onychoscopic Analysis of Cyclophosphamide-Induced Polydactylic Bluish-Gray Discoloration in a Case of Pemphigus Foliaceus.一例落叶型天疱疮患者中，环磷酰胺诱导的多指蓝灰色变色的甲镜分析
Cureus. 2024 Mar 30;16(3):e57233. doi: 10.7759/cureus.57233. eCollection 2024 Mar.
3
Cancer Chemotherapy-associated Pigmentation of the Oral Mucosa.口腔黏膜癌症化疗相关性色素沉着。
In Vivo. 2023 Jul-Aug;37(4):1880-1885. doi: 10.21873/invivo.13280.
本文引用的文献
1
Chromonychia secondary to chemotherapy.化疗继发的甲变色
Case Rep Dermatol. 2013 Jun 6;5(2):163-7. doi: 10.1159/000351874. Print 2013 May.
2
Melanonychia.甲下黑素沉着
Dermatol Res Pract. 2012;2012:952186. doi: 10.1155/2012/952186. Epub 2012 Jun 27.
3
Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen.环磷酰胺化疗方案后出现的异常指甲色素沉着。
Indian J Pharmacol. 2010 Aug;42(4):243-4. doi: 10.4103/0253-7613.68433.
4
Patterns of chromonychia during chemotherapy in patients with skin type V and outcome after 1 year of follow-up.皮肤类型 V 的患者在化疗期间的甲纵嵴模式及其 1 年随访后的结果。
Clin Exp Dermatol. 2009 Dec;34(8):e920-6. doi: 10.1111/j.1365-2230.2009.03713.x.
5
Nail toxicity induced by cancer chemotherapy.癌症化疗引起的指甲毒性。
J Oncol Pharm Pract. 2009 Sep;15(3):143-55. doi: 10.1177/1078155208100450. Epub 2009 Jan 26.
6
Pigmented nail disorders.甲色素沉着异常
Dermatol Clin. 2006 Jul;24(3):329-39. doi: 10.1016/j.det.2006.03.012.
7
Longitudinal melanonychia.纵向黑甲
Dermatol Surg. 2001 Jun;27(6):580-4.
8
Drug-induced nail disorders: incidence, management and prognosis.药物性指甲疾病：发病率、管理与预后
Drug Saf. 1999 Sep;21(3):187-201. doi: 10.2165/00002018-199921030-00004.
Zotero 插件